Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generation Program prevention study of CAD106 and CNP520 in people at risk for Alzheimer's disease
2015-002715-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amilomotide and umibecestat in Alzheimer's disease (AD) (4 arms), sponsored by Novartis. Primary endpoint: Time-to-event for onset of MCI due to Alzheimer's disease or Alzheimer's dementia. Started Mar 2016; status: completed.
02
Drugs
amilomotideumibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-002715-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002715-15.